Navigation Links
Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
Date:7/23/2013

seeking to enhance the immune system to combat cancer," commented Mark Fletcher, Generex's President & Chief Executive Officer.  "Recent announcements by Merck and Bristol-Myers Squibb of favourable clinical trial data suggest that immunotherapeutic drugs may significantly impact the treatment of cancer.  We look forward to additional data from the Antigen Express AE37 breast cancer vaccine trial this fall as we seek Phase III partnership opportunities in the context of the industry focus on immunotherapeutic treatments of cancer."

The Antigen Express AE37 vaccine is designed to stimulate the immune system to target HER2 on breast cancer cells at low levels independent of immune type of the person.  AE37 targets an early breast cancer patient population of unmet need several times larger than those treated with Herceptin.  In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional potential advantage is that the immunological memory induced by AE37 means the immune system may continue to scan for and kill HER2 cancer cells long after AE37 treatment has been completed.

Herceptin is approved for metastatic and early stage breast cancer patients. Its 2010 annual sales were nearly $6 Billion.  Given that the initial target population for AE37 in early stage breast cancer patients is twice that of Herceptin, the market potential for AE37 is clear.

About Generex Bio
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
2. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
3. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
4. Generex Announces Date of Annual Stockholders Meeting
5. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Secures Commitments for $3.6M Capital Raise
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
10. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... 06, 2015 , ... Proove Biosciences , a commercial ... Medical Advisory Board meeting in Palm Springs, California. At the bi-annual meeting, the ... discuss new clinical practice and research ideas. The Board also discussed the development ...
(Date:7/6/2015)... 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company ... , Viveve,s Chief Executive Officer, and Scott Durbin , ... July 9, 2015. , , , DATE:    ... , , TIME:     , , , 12:15 PM ... , http://tinyurl.com/viveve   ,    ...
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces that ... Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ) ... in United States District Court, Central District of ... on behalf of a class consisting of all persons ... 2014 and May 13, 2015 inclusive (the "Class Period").  ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... Pioneer in High Throughput SNP Discovery Brings ... Oct. 14 BioNanomatrix, Inc., a developer,of ... and biomedical research, today announced the appointment ... Ph.D., to its Scientific,Advisory Board (SAB). Dr. ...
... offers unique opportunities to advance the life sciences ... biological materials with unprecedented resolution. The ability to ... of genomics, proteomics and cell adhesion, and may ... screening and disease detection, even when sample volumes ...
... of Late Stent Thrombosis Reported in CUSTOM I, II, and III ... ... PARK, Calif., Oct. 13 ,XTENT, Inc. (Nasdaq: XTNT ) today announced ... that reinforces the,efficacy of the Custom NX(R) drug eluting stent (DES) system ...
Cached Biology Technology:BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board 2Researchers write protein nanoarrays using a fountain pen and electric fields 2Researchers write protein nanoarrays using a fountain pen and electric fields 3Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years 2Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years 3
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/16/2015)... Fingerprint Cards has received an order ... company,s portfolio from one of its module partners in ... place during the third quarter 2015. The sensors will be ... Jörgen Lantto, CEO of FPC, comments: " This ... interest from smartphone OEMs in integrating touch fingerprint sensors in ...
(Date:6/15/2015)... A new report [ 1 ] ... consumers using mobile banking applications want their mobile devices to ... instead of having to prove who they are with passwords ...   -   The Fusion of Financial Services, Mobile and ... channel used by Gen X and Gen Y to access ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... Tide" event that occurred off the coast of El ... some 200 sea turtles, according to test results released ... organizations. , Responding to requests from the Salvadoran government ... WCS veterinary pathologist Dr. Julie White journeyed to the ...
... McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins have ... what many have termed "junk" DNA and identified regions ... that these control regions from different species don't have ... will be published online at Science Express March 23. ...
... at the McKusick-Nathans Institute of Genetic Medicine at Johns ... of analyzing what many have termed "junk" DNA and ... have found that these control regions from different species ... The study will be published online at Science Express ...
Cached Biology News:Red Tide causes sea turtle die-off in El Salvador 2Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice 2Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice 3Junk DNA may not be so junky after all 2Junk DNA may not be so junky after all 3
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
... System is the cost-effective solution for entry ... to common research imaging tasks, MetaVue enables ... simple image analysis. Compatibility with MetaMorphs ... that MetaVue has the power to drive ...
Sterile, Cell culture tested...
... many modifications to the original formulas in efforts ... play an important role in tissue,culture. A salt ... osmotic balance in the medium and to provide ... is as valuable today as when it was ...
Biology Products: